Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Alaunos Therapeutics (TCRT) Other Non Operating Income (2016 - 2025)

Alaunos Therapeutics (TCRT) has disclosed Other Non Operating Income for 15 consecutive years, with $28000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Other Non Operating Income rose 21.74% year-over-year to $28000.0, compared with a TTM value of $79000.0 through Sep 2025, down 65.04%, and an annual FY2024 reading of $133000.0, down 87.31% over the prior year.
  • Other Non Operating Income was $28000.0 for Q3 2025 at Alaunos Therapeutics, up from $19000.0 in the prior quarter.
  • Across five years, Other Non Operating Income topped out at $477000.0 in Q1 2023 and bottomed at -$31000.0 in Q2 2021.
  • Average Other Non Operating Income over 5 years is $92789.5, with a median of $28000.0 recorded in 2025.
  • The sharpest move saw Other Non Operating Income tumbled 410.0% in 2021, then soared 12400.0% in 2022.
  • Year by year, Other Non Operating Income stood at $2000.0 in 2021, then skyrocketed by 12400.0% to $250000.0 in 2022, then tumbled by 57.6% to $106000.0 in 2023, then crashed by 87.74% to $13000.0 in 2024, then surged by 115.38% to $28000.0 in 2025.
  • Business Quant data shows Other Non Operating Income for TCRT at $28000.0 in Q3 2025, $19000.0 in Q2 2025, and $19000.0 in Q1 2025.